Cipla Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Cipla kazanç ve gelirin sırasıyla yıllık 7.3% ve 8.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 7.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15% olacağı tahmin edilmektedir.

Anahtar bilgiler

7.3%

Kazanç büyüme oranı

7.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	0%
Gelir büyüme oranı	8.2%
Gelecekteki özkaynak getirisi	15.0%
Analist kapsamı	Good
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BDL:CIPLA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	320,767	53,247	42,494	52,327	33
3/31/2026	300,926	52,190	40,725	50,859	37
3/31/2025	273,960	46,941	35,895	49,634	36
9/30/2024	262,642	44,751	29,520	45,008	N/A
6/30/2024	258,922	43,035	N/A	N/A	N/A
3/31/2024	255,367	41,216	27,846	41,339	N/A
12/31/2023	251,163	37,082	N/A	N/A	N/A
9/30/2023	243,407	34,532	25,988	37,924	N/A
6/30/2023	235,108	31,112	N/A	N/A	N/A
3/31/2023	225,593	28,019	20,736	32,377	N/A
12/31/2022	222,187	26,383	N/A	N/A	N/A
9/30/2022	218,874	25,660	20,120	29,160	N/A
6/30/2022	216,105	24,884	N/A	N/A	N/A
3/31/2022	217,078	25,168	26,285	33,259	N/A
12/31/2021	210,718	25,681	N/A	N/A	N/A
9/30/2021	207,616	25,876	28,362	37,113	N/A
6/30/2021	202,801	25,417	N/A	N/A	N/A
3/31/2021	191,205	24,049	29,418	37,552	N/A
12/31/2020	188,779	22,374	N/A	N/A	N/A
9/30/2020	180,802	18,403	23,627	31,968	N/A
6/30/2020	174,377	16,462	N/A	N/A	N/A
3/31/2020	170,805	15,465	20,684	30,685	N/A
12/31/2019	171,206	16,678	N/A	N/A	N/A
9/30/2019	167,572	16,489	18,294	25,720	N/A
6/30/2019	163,733	15,546	N/A	N/A	N/A
3/31/2019	163,232	15,277	11,640	16,911	N/A
12/31/2018	155,224	13,391	N/A	N/A	N/A
9/30/2018	154,287	14,074	N/A	N/A	N/A
6/30/2018	154,992	14,530	N/A	N/A	N/A
3/31/2018	151,053	14,105	N/A	14,628	N/A
12/31/2017	147,618	11,701	N/A	N/A	N/A
9/30/2017	144,951	11,444	N/A	N/A	N/A
6/30/2017	141,637	10,762	N/A	N/A	N/A
3/31/2017	143,340	10,064	N/A	23,818	N/A
12/31/2016	142,509	11,213	N/A	N/A	N/A
9/30/2016	137,547	10,071	N/A	N/A	N/A
6/30/2016	134,335	12,219	N/A	N/A	N/A
3/31/2016	135,480	13,600	N/A	17,408	N/A
12/31/2015	135,044	16,847	N/A	N/A	N/A
9/30/2015	131,633	16,694	N/A	N/A	N/A
6/30/2015	124,782	15,368	N/A	N/A	N/A
3/31/2015	113,454	11,808	N/A	11,734	N/A
12/31/2014	106,195	11,818	N/A	N/A	N/A
9/30/2014	105,627	11,383	N/A	N/A	N/A
6/30/2014	104,164	11,976	N/A	N/A	N/A
3/31/2014	101,734	13,884	N/A	15,633	N/A
12/31/2013	94,330	14,042	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CIPLA 'nin tahmini kazanç büyümesi (yıllık 7.3% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: CIPLA şirketinin kazançlarının (yıllık 7.3% ) Luxembourg pazarından (yıllık 13.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CIPLA şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: CIPLA şirketinin gelirinin (yıllık 8.2% ) Luxembourg pazarından (yıllık 4.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CIPLA şirketinin gelirinin (yıllık 8.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CIPLA 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15 %).

Cipla Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Cipla Limited, Annual General Meeting, Aug 20, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Cipla Limited Announces Executive Changes

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi

Cipla Limited Recommends Dividend for the Year 2021-22

Cipla Limited Announces Commercialisation of `RT-Direct' multiplex COVID-19 RT PCR Test kit in India

Cipla Limited to Report Q4, 2022 Results on May 10, 2022

Cipla Limited Announces Resignation of Kedar Upadhye from the Position of Global Chief Financial Officer

Cipla Limited and Cipla USA, Inc. Receive Final Approval for Lanreotide Injection

Cipla Limited (NSEI:CIPLA) entered into an agreement to acquire 33% stake in Clean Max Auriga Power LLP for INR 60 million.

Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)

Cipla Receives Final Approval for Generic Version of Sunovion Pharmaceuticals, Inc.'S Brovana® (Arformoterol Tartrate Inhalation Solution 15 Mcg/ 2Ml)

Roche India and Cipla Limited Announces First Batch of the Antibody Cocktail

Cipla Limited Announces Commercialization of Polymerase Chain Reaction (RT-PCR) Test Kit `ViraGen' for COVID-19 in India, in Partnership with Ubio Biotechnology Systems Pvt. Ltd

Cipla Limited Recommends Dividend for the Year 2020-21

Cipla Limited's Subsidiary, Cipla Gulf Fz Lcc Expands Its Partnership with Alvotech for the Marketing and Distribution of Four Biosimilar Medicines in Australia and New Zealand

Cipla Limited Announces Partnership with the Premier Medical Corporation Private Limited for Commercialisation of the Rapid Antigen Test Kits for COVID-19 in India

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID (Lenalidomide) with Cipla

Cipla Limited Launches Covi-G for COVID-19 Rapid Antibody Detection

Cipla Limited Receives Final Approval for Generic Version of Biogen Idec Inc.'S Tecfidera® (Dimethyl Fumarate Dr Capsules 120Mg, 240Mg and 120Mg/240Mg Starter Pack)

Cipla Limited Receives Final Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Dimethyl Fumarate DR Capsules Starter Pak

Cipla Limited Launches Generic Version of Broad-Spectrum Anti-Viral Drug Remdesivir (Branded Cipremi), to Be Used on Critically Ill Covid Patients in the Hospitals

Cipla Limited to Report Q3, 2021 Results on Feb 05, 2021

Cipla Limited to Report Q1, 2021 Results on Aug 07, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin